Mergers & Acquisitions, Explained: The 2026 Field Guide
What mergers & acquisitions covers, why it matters in 2026, and the numbers decision-makers should know.
Executives keep asking the same question about mergers & acquisitions. Consolidation across digital health's busiest M&A run since 2021. This explainer sets out what the category actually covers, why it has moved to the center of funding & m&a strategy, and the numbers every decision-maker should have at hand.
What it covers
Consolidation across digital health's busiest M&A run since 2021. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Funding & M&A coverage, and its daily developments stream into the live Mergers & Acquisitions feed.
Why it matters in 2026
Consider the current numbers: 115 acquisitions made the first half the busiest M&A run since 2021.
Meanwhile, talkiatry's $210 million Series D anchored mental health's seventh straight year atop the clinical funding charts (our coverage).
Meanwhile, garner Health raised back-to-back rounds reaching a $2.74 billion valuation (our coverage).
What to watch next
Three signals will tell you where mergers & acquisitions goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The direction of travel is clear; the pace will be set by reimbursement and by the evidence base now accumulating. For the latest developments, follow our continuously updated Mergers & Acquisitions topic page.